Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
July 25, 2018 16:30 ET
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts,...
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
July 25, 2018 10:30 ET
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts,...
Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018
July 20, 2018 08:39 ET
|
Biogen Inc.
CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational...
Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
July 18, 2018 07:30 ET
|
Biogen Inc.
Ongoing Alzheimer’s disease research programs target possible causes of the disease through multiple modalitiesData to be presented from Alzheimer’s disease clinical development portfolio including...
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
July 05, 2018 19:30 ET
|
Biogen Inc.
The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta...
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
June 28, 2018 16:06 ET
|
Biogen Inc.
Biogen will pay Samsung BioLogics approximately $700 million to increase its ownership in Samsung Bioepis to approximately 49.9%Transaction expected to close in the second half of 2018 CAMBRIDGE,...
Biogen to Report Second Quarter 2018 Financial Results on July 24, 2018
June 25, 2018 16:01 ET
|
Biogen Inc.
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2018 financial results on Tuesday, July 24, 2018, before the financial...
Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018
June 19, 2018 16:01 ET
|
Biogen Inc.
CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday,...
INVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKS
December 13, 2017 13:13 ET
|
Azzad Funds
Falls Church, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SOURCE - AZZAD ASSET MANAGEMENT Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information...
Streetwise Reports Examines Promising 'Hot' Alzheimer's Market for Biotech with 'Novel' Drug Candidate
November 23, 2017 08:45 ET
|
Streetwise Reports Llc
SAN FRANCISCO, Nov. 23, 2017 (GLOBE NEWSWIRE) -- André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's...